Leuben (Bendamustine) is an anti-tumor drug.
Bendamustine has an antineoplastic effect, confirmed in numerous in vitro studies on various tumor cell lines, such as breast cancer, non-small cell and small cell lung cancer, ovarian cancer and various types of leukemia, as well as colon cancer, melanoma, renal cell carcinoma, malignant neoplasms of the prostate gland and brain and in vivo – on various experimental models of tumors – melanoma, breast cancer, sarcoma, lymphoma, leukemia and small cell lung cancer.
Bendamustine promotes the formation of cross-linking of DNA molecules due to alkylation. As a result, the matrix function of DNA and its synthesis are disrupted. There is also evidence that bendamustine has additional antimetabolic properties (purine analogue effect).
Leuben (Bendamustine) shows little to no cross-resistance in human tumor cell lines with different resistance mechanisms.